Related Experiment Video
Updated: Feb 18, 2026

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions
Published on: October 30, 2016
Boosting Natural Killer Cell-Based Immunotherapy with Anticancer Drugs: a Perspective
Loredana Cifaldi1, Franco Locatelli2, Emiliano Marasco3
1Department of Pediatric Haematology/Oncology, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy.
Abstract:
Natural killer (NK) cells efficiently recognize and kill tumor cells through several mechanisms including the expression of ligands for NK cell-activating receptors on target cells. Different clinical trials indicate that NK cell-based immunotherapy represents a promising antitumor treatment. However, tumors develop immune-evasion strategies, including downregulation of ligands for NK cell-activating receptors, that can negatively affect antitumor activity of NK cells, which either reside endogenously, or are adoptively transferred. Thus, restoration of the expression of NK cell-activating ligands on tumor cells represents a strategic therapeutic goal. As discussed here, various anticancer drugs can fulfill this task via different mechanisms. We envision that the combination of selected chemotherapeutic agents with NK cell adoptive transfer may represent a novel strategy for cancer immunotherapy.
Insights
Natural killer (NK) cell immunotherapy shows promise against cancer. Restoring NK cell-activating ligands on tumor cells using anticancer drugs can enhance NK cell antitumor activity, potentially improving immunotherapy outcomes.
Area of Science:
- Immunology
- Oncology
- Pharmacology
Background:
- Natural killer (NK) cells are crucial for recognizing and eliminating tumor cells.
- NK cell-based immunotherapy is a promising cancer treatment approach.
- Tumors evade NK cell attacks by downregulating activating ligands.
Purpose of the Study:
- To explore strategies for restoring NK cell-activating ligands on tumor cells.
- To investigate the potential of anticancer drugs in enhancing NK cell immunotherapy.
- To propose a novel combination therapy for cancer treatment.
Main Methods:
- Review of mechanisms by which NK cells kill tumor cells.
- Analysis of tumor immune evasion strategies.
- Evaluation of how anticancer drugs affect NK cell-activating ligand expression.
Main Results:
- Anticancer drugs can restore the expression of NK cell-activating ligands on tumor cells.
- Restoring these ligands can overcome tumor immune evasion.
- This restoration enhances NK cell-mediated antitumor activity.
Conclusions:
- Restoring NK cell-activating ligands is a key therapeutic goal.
- Anticancer drugs can be utilized to achieve this restoration.
- Combining chemotherapy with NK cell adoptive transfer offers a novel cancer immunotherapy strategy.
More Related Videos
Related Concept Videos
Tumor Immunotherapy
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

